Immunoblot analyses validated that overexpression of NURR1 could enhance the expressions of multiple mesenchymal cell markers (including N-cadherin, vimentin, MMP9) but suppress the expressions of epithelial cell markers (E-cadherin, ZO-1) in prostate cancer cells; conversely, its knockdown could reverse the expressions of these EMT markers in prostate cancer cells (Figs. 6E, F). Here, CDH2 is linked to prostate carcinoma.